Micropulse Laser Therapy For the Treatment of DME
Micropulse Laser Therapy For the Treatment of DME
A less destructive laser may offer greater benefits for treating edema.
DAVID D. GOSSAGE, DO, FAAO, FAOCO
|David D. Gossage, DO, FAAO, FAOCO, practices with Gossage Eye Institute and Optical in Hillsdale, MI. He reports minimal financial interest in Iridex. Dr. Gossage can be reached via e-mail at email@example.com.
As a disease defined by high blood glucose levels that affect the body’s ability to produce or use insulin,1 diabetes afflicts 25.8 million children and adults in the United States. As many as 79 million Americans have prediabetes.2
In 2012, the cost of diagnosed diabetes in the United States was $245 billion.2 This enormous economic impact, due to the cost of treatment in addition to lost work productivity, has led to diabetes becoming one of the leading healthcare concerns globally.
Although proliferative diabetic retinopathy can lead to neovascular glaucoma, cicatricial retinal detachment, and vitreous hemorrhage, the majority of vision loss in diabetes is still due to diabetic macular edema and the leakage of microaneurysms in the central macula.
Because diabetic retinopathy has become the leading cause of new blindness in adults in their prime years of life, many studies have been undertaken to develop treatment options to slow its progression.
The Early Treatment of Diabetic Retinopathy Study (ETDRS) was among the first studies to evaluate the use of laser treatment to slow the progression of DME and vision loss. It concluded that laser photocoagulation is beneficial in the treatment of DME.3
A milder, but more extensive, laser technique was subsequently proposed to minimize possible side effects, such as inadvertent foveal burn, enlarged scar formation, expanded scotoma, and choroidal neovascularization,4,5 and the modified EDTRS protocol is still the most prominent treatment guideline today.6
In more recent years, pharmacotherapy injections — particularly the use of anti-VEGF — have been advocated for the treatment of DME and other retinal diseases, involving vascular etiologies. The RISE and RIDE studies examined the efficacy of ranibizumab (Lucentis, Genentech, South San Francisco, CA) for treatment of DME, demonstrating that it improved vision, reduced the risk of further vision loss, and improved macular edema with less likelihood of developing PDR, compared to sham injections.7 Improvement in mean BCVA and decreases in central foveal thickness (measured on OCT) have led to the use of ranibizumab as a i rst-line therapy for the treatment of DME. Injections show results rapidly, often resulting in a “wow” effect for both patient and physician.
However, therapy may require frequent and ongoing injections, and side effects can include endophthalmitis, retinal detachments, increases in intraocular pressure, thromboembolic events, and even fatal events in DME patients.7 Other studies regarding the use of anti-VEGF for the treatment of DME have included the DRCR.net’s Protocol I, which demonstrated combination anti-VEGF and continuous wave (CW) laser was better than CW laser alone for patients with DME at one year.8,9
Similar studies with comparable results included READ-2,10,11 RESOLVE,12,13 and RESTORE,14 which looked at edema involving the central macula.
Figure 1. Patient A with type 1 DM and DME, pre-MPLT with visual acuity of 20/20.
Figure 2. Patient A, post MPLT one month after treatment, with resolution of DME and visual acuity of 20/20. The patient had no anti-VEGF treatment at the time of MPLT.
On the horizon is the DA VINCI study, a phase 2 trial utilizing aflibercept (Eylea, Regeneron, Tarrytown, NY) for the treatment of DME, which has demonstrated significant gains in BCVA compared to laser alone in early reports.15
FIRST, DO NO HARM
Another treatment option for DME includes the use of micro-pulse laser therapy (MPLT) (Iridex, Mountain View, CA). MPLT utilizes technology that chops a CW laser beam into a train of repetitive microsecond pulses, allowing tissue to cool between pulses to reduce thermal buildup.
Micropulse laser induces a stress response that results in antiangiographic activity without the thermal destruction the conventional CW laser or subthreshold CW laser can cause. Research has shown that destruction of retinal pigment epithelial cells is not necessary to produce a therapeutic result.16
Research has shown that destruction of RPE cells is not necessary to produce therapeutic results.
Further, studies have also shown MPLT to be as effective for treating DME as conventional, more damaging photocoagulation17-19 and that MPLT can improve visual sensitivity.17 However, head-to-head studies of MPLT vs pharmacotherapy have not yet been undertaken.
In my practice, if the patient presents with clinically significant macular edema, I prefer to begin with anti-VEGF therapy for several sessions to help reduce the DME faster and restore BCVA. I will then augment treatment with MPLT to maintain the effect of anti-VEGF therapy longer and to aid in the removal of persistent DME, especially subfoveal.
I feel comfortable knowing that I am not creating any thermal damage in the fovea and that I may be able to reduce the amount of anti-VEGF treatments needed in the future for a given patient.
Many patients with the disease are resistant to having intraocular injections or who are at high risk for systemic side effects associated with anti-VEGF therapy. For these patients, I choose to perform MPLT as the initial therapy (Figures 1-3).
Micropulse laser can be delivered directly over areas of edema, including the central fovea. The effect of the laser is not as fast as anti-VEGF therapy and may require several months to obtain the desired result. However, the effects of the MPLT appear longer lasting than anti-VEGF therapy alone.
Figure 3. Patient B with type 2 DM, pre-MPLT and three months post-MPLT. Visual acuity went from 20/50 to 20/30 with resolution of DME. The patient had no anti-VEGF treatment at the time of MPLT.
Because MPLT does no damage to the tissue, I can add an additional treatment in three to six months, if indicated. I can follow patients clinically and with OCT for the resolution of DME.
My current treatment protocol for the Iridex IQ532 laser with micropulse is as follows: I begin with the laser set in traditional CW settings. After placing a Mainster lens on the eye, I place a test spot in a nonedematous area of the retina, using a 100-??? spot size, 100-msec duration, and 100 mW of power.
I then titrate the power up by 10-50 mW, moving to a new area each time, until I note a thermal reaction (white burn). I then switch the laser to the micropulse setting and place it into a 5% duty cycle. I maintain the 100-μm spot size and double the duration and power. I then perform MPLT over the area of edema with a high-density grid treatment.
THE SHIFTING DME TREATMENT PARADIGM
With so many different modalities available for the treatment of DME, choosing the best treatment for a given patient can be difficult. Since the development of anti-VEGF therapy and a better understanding of the mechanism of action, we have been able to improve patient outcomes and slow the progression of DME in many diabetic individuals.20
However, we must be cautious when using anti-VEGF therapy in some patients who may be compromised systemically. As physicians, our first goal in any treatment is to do no harm. For me, MPLT, utilizing the IQ 532 laser, has made the treatment of DME safer and more effective than anti-VEGF treatment alone or with CW laser. RP
1. American Diabetes Association. Available at: http://www.diabetes.org. Accessed April 9, 2013.
2. American Diabetes Association. Diabetes statistics. Available at: http://www. diabetes.org/diabetes-basics/diabetes-statistics. Accessed April 9, 2013.
3. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796-1806.
4. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549-1551.
5. Roider J. Laser treatment of retinal diseases by subthreshold laser effects. Semin Ophthalmol. 1999;14:19-26.
6. Writing Committee for the Diabetic Retinopathy Clinical Research Network; Fong DS, Strauber SF, Aiello LP, et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125:469-480.
7. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
8. Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077.
9. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Diabetic Retinopathy Clinical Research Network. Ophthalmology. 2011;118:609-614.
10. Nguyen QD, Shah SM, Heier JS, et al. READ-2 Study Group Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology. 2009;116:2175-2181.e1.
11. Nguyen QD, Shah SM, Khwaja AA, et al; READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-2151.
12. Wolf S, Massin P, Bandello F, et al; RESOLVE Study Group. Safety and efficacy of ranibizumab treatment in patients with diabetic macular edema: 12-month results of the RESOLVE Study. Paper presented at: Association for Research in Vision and Ophthalmology meeting; May 3-7, 2009; Fort Lauderdale, FL.
13. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care.
14. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-625.
15. Do DV, Nguyen QD, Boyer D, et al; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-EYE in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658-1665.
16. Wilson A. Argon laser photocoagulation-induced modification of gene expression in the retina. Invest Ophthalmol Vis Sci. 2003;44:1426-2434.
17. Vujosevic S, Bottega E, Casciano M, et al. Microperimetry and fundus modiied early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010;30:908-916.
18. Luttrull JK, Sramek C, Palanker D, et al. Long-term safety, high-resolution imaging, retinovascular macular edema. Retina. 2012;32:375-386.
19. Lavinsky D, Cardillo JA, Melo LA Jr., Dare A, Farah ME, Belfort R Jr. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52:4314-4323.
20. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmology. 2012;130:1145-1152.
Retinal Physician, Volume: 10 , Issue: June 2013, page(s): 36 - 39